Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/11/2018
Entire Document
 

Item 8.01. Other Events.

On January 9, 2018, BeiGene, Ltd. (the “Company”) issued a press release announcing that it had entered into a commercial supply agreement with Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (“Boehringer”) for the Company’s anti-PD-1 antibody, tislelizumab (BGB-A317), which will be manufactured at Boehringer’s facility in Shanghai, China. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description
99.1 Press Release issued on January 9, 2018



© 2016 BeiGene. All Rights Reserved.